Array BioPharma Inc. · Boulder, CO United States ·(NASDAQ (GM): ARRY)
Company Description
View Array BioPharma Inc. Locations On A US Map
This link will open in a new window
This link will open in a new window Array BioPharma is discovering it's best to be your own boss. Once devoted to discovering drug candidates for other firms, the company is increasingly focused on its own drug development efforts in the areas of cancer and inflammatory disease. Candidates in early clinical trials include potential therapies for breast cancer (ARRY-543) and rheumatoid arthritis (ARRY-162). Array has also out-licensed some cancer programs to AstraZeneca and Genentech ; ARRY-886, developed with AstraZeneca, is in clinical trials for melanoma. Drug discovery services for third parties still account for a big chunk of business; Array has R&D agreements with InterMune , Ono Pharmaceutical , Celgene , and others. To read the full description, subscribe now.
Call Now at 866-464-3202 or Click here for a Free Hoover's Trial!
Key Array BioPharma Inc. Financials
| Company Type | Public - NASDAQ (GM): ARRY Headquarters |
| Fiscal Year-End | June |
| 2009 Sales (mil.) | $25.0 |
| 2009 Employees | 355 |
Array BioPharma Inc. Executives
22 executives listed for Array BioPharma Inc.'s Boulder, CO location.
| Title | Name & Bio | Contact |
| Chairman | Kyle Lefkoff | Network |
| CEO and Director | Robert Conway | Network |
| President, Chief Scientific Officer, and Director | Kevin Koch | Network |
Competition
Competitive Landscape for Array BioPharma Inc.
Demand for biotechnology research in the fields of medicine, agriculture, food, and science is driven by insurers' willingness to pay for new medical treatments, the global need to produce more food for a rapidly expanding population, and scientists' desire to find solutions for complex scientific and medical issues. Funding for biotech research is often provided by venture capital funds hoping to cash in on new products. The profitability of individual companies depends on the discovery and effective marketing of new products. Because the market for potential products is so large, small biotechnology companies can co-exist successfully with large ones if they have expertise in a particular line of research. The industry is capital intensive: average annual revenue per worker is more than $350,000. Biotech firms face stiff competition from pharmaceutical and other companies seeking to be first with a new product or discovery. To read the full description, subscribe now.Top Array BioPharma Inc. Competitors
Call Now at 866-464-3202 or Click here for a Free Hoover's Trial!